Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit in Treatment-Naïve CLL

Fixed-duration therapy with venetoclax plus obinutuzumab led to 60% reduction in the risk of progression or death compared with chlorambucil plus obinutuzumab, with benefit seen regardless of TP53 or IGHV mutation status, in previously untreated patients with chronic lymphocytic leukemia.

Related Keywords

Lugano ,Ticino ,Switzerland ,Vienna ,Wien ,Austria ,Germany ,Othman Al Sawaf ,University Of Cologne ,International Conference On Malignant Lymphoma ,Division Of Hematology ,Astrazeneca ,Intensive Care ,Annual International Conference ,Cumulative Illness Rating Scale ,All Binet ,International Conference ,Malignant Lymphoma ,Obinutuzumab ,Venetoclax ,Tp53 ,Chronic Lymphocytic Leukemia ,Cll ,Fighv ,Chlorambucil ,Icml ,